Collegium Q2 revenue rises 6%
COLL•Updated 2026 guidance
Collegium lowered 2026 product revenues, net guidance to $825 mln-$855 mln from $865 mln-$895 mln.
The company raised 2026 AZSTARYS revenue guidance to $65 mln-$75 mln from $60 mln-$70 mln.
It maintained 2026 JORNAY PM revenue guidance at $190 mln-$200 mln.
Quarterly revenue and EPS
Collegium's Q2 revenue rose 6% year over year, slightly missing analyst expectations. Adjusted EPS for Q2 beat analyst expectations.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Slight Miss* | $199.90 mln | $201.21 mln (5 Analysts) |
| Q2 Adjusted EPS | Beat | $1.92 | $1.72 (5 Analysts) |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst coverage and valuation
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the pharmaceuticals peer group is "buy".
Wall Street's median 12-month price target for Collegium Pharmaceutical Inc is $56.00, about 56.7% above its August 5 closing price of $35.74.
The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 5 three months ago.
